According to Revance Therapeutics's latest financial reports and stock price the company's current Operating Margin is -63.25%. At the end of 2023 the company had an Operating Margin of -130.03%.
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.